Employing CETSA® in Primary Screening for p53 Binders

CETSA p53 Screening: Uncovering Potential Cancer Therapeutics Targeting p53, a key tumor suppressor protein often labeled “undruggable,” poses a major challenge in oncology research. Yet, overcoming this challenge could unlock transformative cancer treatments. Our latest study leverages CETSA p53 screening-a technique using the Cellular Thermal Shift Assay-to identify small molecules that bind to p53 in live cells. Specifically, we screened for p53 binders in intact SK-BR-3 breast cancer cells, revealing compounds that not only interact with p53 but also stabilize its active form. These findings open new avenues for targeting p53 in cancers where it plays a critical role. Unlike traditional high-throughput screening (HTS) methods, which often rely on artificial systems, CETSA-b...